Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan‐Malte Placke, Selma Ugurel, Mona Kimmig et al.|EBioMedicine|2023Cited by 49
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl Maximilian Thielmann, Klaus Griewank, Johanna Matull et al.|European Journal of Cancer|2021Cited by 33
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl Maximilian Thielmann, Klaus Griewank, Johanna Matull et al.|European Journal of Cancer|2021Cited by 20
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaJan‐Malte Placke, Selma Ugurel, Camille Soun et al.|Frontiers in Oncology|2021Cited by 19
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Henner Stege et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 18